IAP proteins as targets for drug development in oncology

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 1285-1304

  Dubrez, Laurence ^a,b   Berthelet, Jean ^a,b   Glorian, Valérie ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Antitumor therapy; Apoptosis; Smac mimetics

Indexed keywords

AEG 35156; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AT 406; AZACITIDINE; BIRINAPANT; CARBOPLATIN; CISPLATIN; CYTARABINE; DAUNORUBICIN; DEBIO 1143; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FIRTECAN; GDC 0152; GDC 0917; GEMCITABINE; HGS 1029; IDARUBICIN; INHIBITOR OF APOPTOSIS PROTEIN; IRINOTECAN; LCL 161; LDL 161; PACLITAXEL; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SM 406; SORAFENIB; SURVIVIN; TENIPOSIDE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ASCITES; B CELL LYMPHOMA; BREAST CANCER; BREAST CARCINOMA; BREAST TUMOR; CANCER THERAPY; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; DRUG STRUCTURE; DRUG TARGETING; FATIGUE; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUROPATHY; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; UTERINE TUBE CARCINOMA;

EID: 84884254106     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S33375     Document Type: Review

References (72)

1. Tamm I, Richter S, Scholz F, et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J. 2004;5(6):489-495.
2. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000;6(5):1796-1803.
3. Grzybowska-Izydorczyk O, Cebula B, Robak T, Smolewski P. Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer. 2010;46(4):800-810.
4. Hussain AR, Uddin S, Ahmed M, et al. Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling. J Pathol. 2011;222(2):180-190.
5. Li M, Song T, Yin ZF, Na YQ. XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer. Chin Med J (Engl). 2007;120(6):469-473.
6. Zhang Y, Zhu J, Tang Y, et al. X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma. Diagn Pathol. 2011;6:49.
7. Liu SS, Tsang BK, Cheung AN, et al. Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur J Cancer. 2001;37(9):1104-1110.
8. Xiang G, Wen X, Wang H, Chen K, Liu H. Expression of X-linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis. J Surg Oncol. 2009;100(8):708-712.
9. Moussata D, Amara S, Siddeek B, et al. XIAP as a radioresistance factor and prognostic marker for radiotherapy in human rectal adenocarcinoma. Am J Pathol. 2012;181(4):1271-1278.
10. Augello C, Caruso L, Maggioni M, et al. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer. 2009;9:125.
11. Shi YH, Ding WX, Zhou J, et al. Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology. 2008;48(2):497-507.
12. Hiscutt EL, Hill DS, Martin S, et al. Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy. J Invest Dermatol. 2010;130(9):2250-2258.
13. Ferreira CG, van der Valk P, Span SW, et al. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res. 2001;7(8):2468-2474.
14. Ferreira CG, van der Valk P, Span SW, et al. Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann Oncol. 2001;12(6): 799-805.
15. Brunckhorst MK, Lerner D, Wang S, Yu Q. AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer Biol Ther. 2012;13(9):804-811.
16. Seligson DB, Hongo F, Huerta-Yepez S, et al. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res. 2007;13(20):6056-6063.
17. Krajewska M, Krajewski S, Banares S, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res. 2003;9(13):4914-4925.
18. Ramp U, Krieg T, Caliskan E, et al. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol. 2004;35(8):1022-1028.
19. Yan Y, Mahotka C, Heikaus S, et al. Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Br J Cancer. 2004;91(7):1349-1357.
20. Mizutani Y, Nakanishi H, Li YN, et al. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol. 2007;30(4):919-925.
21. Gu LQ, Li FY, Zhao L, et al. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma. Thyroid. 2009;19(4):347-354.
22. Imoto I, Tsuda H, Hirasawa A, et al. Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res. 2002;62(17):4860-4866.
23. Imoto I, Yang ZQ, Pimkhaokham A, et al. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res. 2001;61(18):6629-6634.
24. Zender L, Spector MS, Xue W, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125(7):1253-1267.
25. Cheng L, Zhou Z, Flesken-Nikitin A, et al. Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency. Oncogene. 2010;29(42):5700-5711.
26. Reardon DA, Michalkiewicz E, Boyett JM, et al. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res. 1997;57(18):4042-4047.
27. Dai Z, Zhu WG, Morrison CD, et al. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet. 2003;12(7): 791-801.
28. Bashyam MD, Bair R, Kim YH, et al. Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia. 2005;7(6):556-562.
29. Esposito I, Kleeff J, Abiatari I, et al. Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. J Clin Pathol. 2007;60(8):885-895.
30. Vallat L, Magdelénat H, Merle-Béral H, et al. The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. Blood. 2003;101(11):4598-4606.
31. Silva KL, Vasconcellos DV, Castro ED, Coelho AM, Linden R, Maia RC. Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia. Apoptosis. 2006;11(2):277-285.
32. Che X, Yang D, Zong H, et al. Nuclear cIAP1 overexpression is a tumor stage- and grade-independent predictor of poor prognosis in human bladder cancer patients. Urol Oncol. 2012;30(4):450-456.
33. Ponnelle T, Chapusot C, Martin L, et al. Subcellular expression of c-IAP1 and c-IAP2 in colorectal cancers: relationships with clinicopathological features and prognosis. Pathol Res Pract. 2003;199(11):723-731.
34. Tanimoto T, Tsuda H, Imazeki N, et al. Nuclear expression of cIAP-1, an apoptosis inhibiting protein, predicts lymph node metastasis and poor patient prognosis in head and neck squamous cell carcinomas. Cancer Lett. 2005;224(1):141-151.
35. Qi S, Mogi S, Tsuda H, et al. Expression of cIAP-1 correlates with nodal metastasis in squamous cell carcinoma of the tongue. Int J Oral Maxillofac Surg. 2008;37(11):1047-1053.
36. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131-144.
37. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2): 115-130.
38. Stanculescu A, Bembinster LA, Borgen K, Bergamaschi A, Wiley E, Frasor J. Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner. Horm Cancer. 2010;1(3):127-135.
39. Akagi T, Motegi M, Tamura A, et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene. 1999;18(42): 5785-5794.
40. Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood. 1999;93(11):3601-3609.
41. El-Mesallamy HO, Hegab HM, Kamal AM. Expression of inhibitor of apoptosis protein (IAP) livin/BIRC7 in acute leukemia in adults: correlation with prognostic factors and outcome. Leuk Res. 2011;35(12): 1616-1622.
42. Choi J, Hwang YK, Sung KW, et al. Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood. 2007;109(2):471-477.
43. Gazzaniga P, Gradilone A, Giuliani L, et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol. 2003;14(1): 85-90.
44. Wang X, Xu J, Ju S, Ni H, Zhu J, Wang H. Livin gene plays a role in drug resistance of colon cancer cells. Clin Biochem. 2010;43(7-8): 655-660.
45. Wang TS, Ding QQ, Guo RH, et al. Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNA-mediated silencing of livin gene. Biomed Pharmacother. 2010;64(5):333-338.
46. Nachmias B, Ashhab Y, Bucholtz V, et al. Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Res. 2003;63(19): 6340-6349.
47. Kim DK, Alvarado CS, Abramowsky CR, et al. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome. Pediatr Dev Pathol. 2005;8(6): 621-629.
48. Nedelcu T, Kubista B, Koller A, et al. Livin and Bcl-2 expression in high-grade osteosarcoma. J Cancer Res Clin Oncol. 2008;134(2): 237-244.
49. Kempkensteffen C, Hinz S, Christoph F, et al. Expression of the apoptosis inhibitor livin in renal cell carcinomas: correlations with pathology and outcome. Tumour Biol. 2007;28(3):132-138.
50. Haferkamp A, Bedke J, Vetter C, et al. High nuclear Livin expression is a favourable prognostic indicator in renal cell carcinoma. BJU Int. 2008;102(11):1700-1706.
51. Kempkensteffen C, Hinz S, Krause H, et al. Expression of splicing variants of the inhibitor of apoptosis livin in testicular germ cell tumors. Tumour Biol. 2008;29(2):76-82.
52. Pluta A, Wrzesien-Kus A, Cebula-Obrzut B, et al. Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients. Leuk Res. 2010;34(10):1308-1313.
53. Mizutani Y, Katsuoka Y, Bonavida B. Low circulating serum levels of second mitochondria-derived activator of caspase (Smac/DIABLO) in patients with bladder cancer. Int J Oncol. 2012;40(4):1246-1250.
54. Pluta P, Cebula-Obrzut B, Ehemann V, et al. Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients. Neoplasma. 2011;58(5):430-435.
55. Arellano-Llamas A, Garcia FJ, Perez D, et al. High Smac/DIABLO expression is associated with early local recurrence of cervical cancer. BMC Cancer. 2006;6:256.
56. Endo K, Kohnoe S, Watanabe A, et al. Clinical significance of Smac/DIABLO expression in colorectal cancer. Oncol Rep. 2009;21(2):351-355.
57. Dobrzycka B, Terlikowski SJ, Bernaczyk PS, et al. Prognostic significance of smac/DIABLO in endometrioid endometrial cancer. Folia Histochem Cytobiol. 2011;48(4):678-681.
58. Xu Y, Zhou L, Huang J, et al. Role of Smac in determining the chemotherapeutic response of esophageal squamous cell carcinoma. Clin Cancer Res. 2011;17(16):5412-5422.
59. Sekimura A, Konishi A, Mizuno K, et al. Expression of Smac/DIABLO is a novel prognostic marker in lung cancer. Oncol Rep. 2004;11(4): 797-802.
60. Mizutani Y, Katsuoka Y, Bonavida B. Prognostic significance of second mitochondria-derived activator of caspase (Smac/DIABLO) expression in bladder cancer and target for therapy. Int J Oncol. 2010;37(2):503-508.
61. Shibata T, Mahotka C, Wethkamp N, Heikaus S, Gabbert HE, Ramp U. Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas. Diagn Mol Pathol. 2007;16(1):1-8.
62. Kempkensteffen C, Hinz S, Christoph F, et al. Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value. J Cancer Res Clin Oncol. 2008;134(5):543-550.
63. Ouyang YQ, zur Hausen A, Orlowska-Volk M, et al. Expression levels of hnRNP G and hTra2-beta1 correlate with opposite outcomes in endometrial cancer biology. Int J Cancer. 2011;128(9):2010-2019.
64. Yang X, Xing H, Gao Q, et al. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. Gynecol Oncol. 2005;97(2):413-421.
65. Hu XY, Xu YM, Chen XC, Ping H, Chen ZH, Zeng FQ. Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia. APMIS. 2006;114(12):893-898.
66. Hu X, Chen X, Ping H, Chen Z, Zeng F, Lu G. Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia. J Huazhong Univ Sci Technolog Med Sci. 2005;25(6):671-673.
67. Lee SH, Lee JW, Kim HS, et al. Immunohistochemical analysis of Omi/HtrA2 expression in stomach cancer. APMIS. 2003;111(5):586-590.
68. Zurawa-Janicka D, Kobiela J, Galczynska N, et al. Changes in expression of human serine protease HtrA1, HtrA2 and HtrA3 genes in benign and malignant thyroid tumors. Oncol Rep. 2012;28(5):1838-1844.
69. Narkiewicz J, Lapinska-Szumczyk S, Zurawa-Janicka D, Skorko-Glonek J, Emerich J, Lipinska B. Expression of human HtrA1, HtrA2, HtrA3 and TGF-beta1 genes in primary endometrial cancer. Oncol Rep. 2009;21(6):1529-1537.
70. Narkiewicz J, Klasa-Mazurkiewicz D, Zurawa-Janicka D, Skorko-Glonek J, Emerich J, Lipinska B. Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer. Clin Biochem. 2008;41(7-8):561-569.
71. Gottfried Y, Voldavsky E, Yodko L, Sabo E, Ben-Itzhak O, Larisch S. Expression of the pro-apoptotic protein ARTS in astrocytic tumors: correlation with malignancy grade and survival rate. Cancer. 2004; 101(11):2614-2621.
72. Elhasid R, Sahar D, Merling A, et al. Mitochondrial pro-apoptotic ARTS protein is lost in the majority of acute lymphoblastic leukemia patients. Oncogene. 2004;23(32):5468-5475.